Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

218
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
218
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.1K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.1K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

136
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
136
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

194
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
194
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

121
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
121
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

117
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
117

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Objective First, Method Second: Why the Estimand Definition Comes First in Pharmacometric Covariate Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Conditional Versus Unconditional Covariate Effects in Pharmacometric Models: Implications for Interpretation, Communication, and Reporting.

CPT: pharmacometrics & systems pharmacology·2026
Same author

The Reference-Corrected Visual Predictive Check: A More Intuitive Diagnostic for Non-Linear Mixed Effects Models.

The AAPS journal·2025
Same author

The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models.

Journal of pharmacokinetics and pharmacodynamics·2025
Same author

Population pharmacokinetic and dose-response models of nepadutant, a selective antagonist of the NK<sub>2</sub> receptors, in infants with colic.

British journal of clinical pharmacology·2024
Same author

Full random effects models (FREM): A practical usage guide.

CPT: pharmacometrics & systems pharmacology·2024

Related Experiment Video

Updated: Sep 4, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.6K

Efficient and relevant stepwise covariate model building for pharmacometrics.

Robin J Svensson1, E Niclas Jonsson1

  • 1Pharmetheus AB, Uppsala, Sweden.

CPT: Pharmacometrics & Systems Pharmacology
|July 19, 2022
PubMed
Summary

New covariate modeling methods, SCM+ and stage-wise filtering, significantly improve efficiency and relevant covariate selection in drug development compared to traditional stepwise covariate model (SCM) procedures.

More Related Videos

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

6.7K
Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

3.4K

Related Experiment Videos

Last Updated: Sep 4, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.6K
Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

6.7K
Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

3.4K

Area of Science:

  • Pharmacometrics
  • Population Pharmacokinetics
  • Drug Development

Background:

  • Covariate modeling is crucial for pharmacometrics in drug development decision-making.
  • The traditional stepwise covariate model (SCM) procedure, while common, suffers from long runtimes and suboptimal covariate selection, particularly in complex Phase III studies.

Purpose of the Study:

  • To introduce and evaluate two novel covariate modeling approaches: SCM+ and stage-wise filtering.
  • To compare the efficiency and relevance of SCM+, SCM+ with stage-wise filtering, and traditional SCM using simulated Phase III pharmacokinetic data.

Main Methods:

  • SCM+ incorporates adaptive scope reduction and modified estimation settings.
  • Stage-wise filtering categorizes covariates by importance (mechanistic, structural, exploratory).
  • All three methods (SCM, SCM+, SCM+ with stage-wise filtering) were applied to simulated Phase III population pharmacokinetic data.

Main Results:

  • SCM+ and SCM+ with stage-wise filtering demonstrated substantial efficiency gains over traditional SCM.
  • Function evaluations were reduced by 70% (SCM+) and 76% (SCM+ with stage-wise filtering).
  • Executed models were reduced by 44% (SCM+) and 70% (SCM+ with stage-wise filtering).
  • SCM+ with stage-wise filtering identified the most relevant covariates among the methods.

Conclusions:

  • SCM+ and stage-wise filtering significantly enhance the efficiency of covariate modeling in drug development.
  • These improved methods facilitate more timely and informed decision-making in the drug development process.
  • The adoption of SCM+ and stage-wise filtering is recommended for optimizing covariate model building.